Latest Japanese recommendations include first nod for Novo's insulin degludec
This article was originally published in Scrip
Executive Summary
Novo Nordisk's Tresiba (insulin degludec) has received its first positive approval opinion worldwide, in Japan, following a regulatory filing in this market last December.
You may also be interested in...
Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments
Biocodex's Diacomit – long approved in the EU – just won FDA approval. That brings the number of drugs cleared for Dravet in the US to two, including GW Pharma's recently endorsed Epidiolex, and the R&D pipeline for this rare seizure disorder is growing.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.